Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310856859> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W4310856859 endingPage "100987" @default.
- W4310856859 startingPage "100987" @default.
- W4310856859 abstract "Riociguat is the first approved treatment for inoperable and persistent/recurrent post-surgery chronic thromboembolic pulmonary hypertension (CTEPH). The RetrospectIve Adempas® stuDy (RiAD) aimed to describe the real-world utilization of riociguat in France.In this retrospective multicentric study in patients initiating riociguat, dosing regimen, co-treatments and clinical characteristics were collected over a 2-year follow-up period.A total of 173 patients (mean age, 71.4 years; female, 63.0%; NYHA II-III, 80.3%) were included from January 2015 to December 2016 in 18 centers. All patients were diagnosed with CTEPH (75.7% inoperable and 20.8% with persistent/recurrent pulmonary hypertension [pH] after surgery) with mean (SD) right atrial pressure 7.6 (4.2) mmHg, mean pulmonary artery pressure 43.0 (11.4) mmHg and mean cardiac output 4.1 (1.1) L/min. Before riociguat initiation, 32.4% of patients previously received at least one pH-specific therapy. At initiation, 93.1% of patients were receiving anticoagulants and 83.2% were not receiving pH-specific co-treatments. Riociguat was initiated at 1 mg three times daily (t.i.d.) in 85.5% of patients and 82.1% were receiving 2.5 mg dose t.i.d. at 24 months. The maximal daily dose of 7.5 mg was never exceeded. At 24 months, the estimated rate of patients still taking riociguat was 78.8% with an estimated mean (SD) time on treatment of 20.1 (0.5) months per patient. No new safety signals were recorded.The results of this real-world study show that riociguat is used in France in accordance with its therapeutic indication in patients with inoperable or persistent/recurrent post-operative CTEPH and confirm its long-term safety." @default.
- W4310856859 created "2022-12-19" @default.
- W4310856859 creator A5005185172 @default.
- W4310856859 creator A5013621523 @default.
- W4310856859 creator A5043511682 @default.
- W4310856859 creator A5055583938 @default.
- W4310856859 creator A5062244421 @default.
- W4310856859 creator A5081412008 @default.
- W4310856859 creator A5089300668 @default.
- W4310856859 creator A5090627602 @default.
- W4310856859 date "2023-06-01" @default.
- W4310856859 modified "2023-10-01" @default.
- W4310856859 title "Riociguat real-world use in patients with chronic thromboembolic pulmonary hypertension: A retrospective, observational cohort study in France" @default.
- W4310856859 cites W2106794486 @default.
- W4310856859 cites W2108559440 @default.
- W4310856859 cites W2115040361 @default.
- W4310856859 cites W2116338856 @default.
- W4310856859 cites W2127994875 @default.
- W4310856859 cites W2156477379 @default.
- W4310856859 cites W2156573757 @default.
- W4310856859 cites W2158098132 @default.
- W4310856859 cites W2161370807 @default.
- W4310856859 cites W2168786509 @default.
- W4310856859 cites W2316662328 @default.
- W4310856859 cites W2794044907 @default.
- W4310856859 cites W2904180601 @default.
- W4310856859 cites W2937499686 @default.
- W4310856859 cites W3102239855 @default.
- W4310856859 cites W3116473131 @default.
- W4310856859 doi "https://doi.org/10.1016/j.resmer.2022.100987" @default.
- W4310856859 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36634552" @default.
- W4310856859 hasPublicationYear "2023" @default.
- W4310856859 type Work @default.
- W4310856859 citedByCount "0" @default.
- W4310856859 crossrefType "journal-article" @default.
- W4310856859 hasAuthorship W4310856859A5005185172 @default.
- W4310856859 hasAuthorship W4310856859A5013621523 @default.
- W4310856859 hasAuthorship W4310856859A5043511682 @default.
- W4310856859 hasAuthorship W4310856859A5055583938 @default.
- W4310856859 hasAuthorship W4310856859A5062244421 @default.
- W4310856859 hasAuthorship W4310856859A5081412008 @default.
- W4310856859 hasAuthorship W4310856859A5089300668 @default.
- W4310856859 hasAuthorship W4310856859A5090627602 @default.
- W4310856859 hasConcept C126322002 @default.
- W4310856859 hasConcept C141071460 @default.
- W4310856859 hasConcept C164705383 @default.
- W4310856859 hasConcept C167135981 @default.
- W4310856859 hasConcept C2776304953 @default.
- W4310856859 hasConcept C2777428986 @default.
- W4310856859 hasConcept C2780930700 @default.
- W4310856859 hasConcept C2780940725 @default.
- W4310856859 hasConcept C71924100 @default.
- W4310856859 hasConceptScore W4310856859C126322002 @default.
- W4310856859 hasConceptScore W4310856859C141071460 @default.
- W4310856859 hasConceptScore W4310856859C164705383 @default.
- W4310856859 hasConceptScore W4310856859C167135981 @default.
- W4310856859 hasConceptScore W4310856859C2776304953 @default.
- W4310856859 hasConceptScore W4310856859C2777428986 @default.
- W4310856859 hasConceptScore W4310856859C2780930700 @default.
- W4310856859 hasConceptScore W4310856859C2780940725 @default.
- W4310856859 hasConceptScore W4310856859C71924100 @default.
- W4310856859 hasFunder F4320309470 @default.
- W4310856859 hasFunder F4320309941 @default.
- W4310856859 hasLocation W43108568591 @default.
- W4310856859 hasLocation W43108568592 @default.
- W4310856859 hasOpenAccess W4310856859 @default.
- W4310856859 hasPrimaryLocation W43108568591 @default.
- W4310856859 hasRelatedWork W1965114391 @default.
- W4310856859 hasRelatedWork W2003581967 @default.
- W4310856859 hasRelatedWork W2797404324 @default.
- W4310856859 hasRelatedWork W2911151436 @default.
- W4310856859 hasRelatedWork W2982422596 @default.
- W4310856859 hasRelatedWork W3093154923 @default.
- W4310856859 hasRelatedWork W3208595465 @default.
- W4310856859 hasRelatedWork W4223504984 @default.
- W4310856859 hasRelatedWork W4306953364 @default.
- W4310856859 hasRelatedWork W4383481543 @default.
- W4310856859 hasVolume "83" @default.
- W4310856859 isParatext "false" @default.
- W4310856859 isRetracted "false" @default.
- W4310856859 workType "article" @default.